Abbott acquires Magnus Medical for $400M to add SAINT TMS to neuromodulation portfolio
Summary
Abbott has agreed to acquire Menlo Park-based Magnus Medical for $400 million upfront plus $150M in milestones tied to FDA clearance and commercial revenue targets. The acquisition adds the SAINT accelerated TMS protocol and Magnus' FDA Breakthrough Device designated program to Abbott's neuromodulation division, which already includes DBS, SCS, and sacral nerve stimulation.
Why it matters
Abbott paying $400M for a pre-clearance TMS company values Magnus' Breakthrough Device designation, pipeline, and founding team's Stanford credentials at a significant premium. This is the first major Big MedTech entry into accelerated TMS and signals the segment is viewed as a major future revenue contributor.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial